Role of cytokines in the mechanism of action of amlodipine: The PRAISE heart failure trial

Journal of the American College of Cardiology

Volumn 30, Issue 1, 1997, Pages 35-41

  Mohler III, Emile R ^a   Sorensen, Leif C ^b   Ghali, Jalal K ^c   Schocken, Douglas D ^d   Willis, Park W ^e   Bowers, John A ^f   Cropp, Anne B ^g   Pressler, Milton L ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f Heart Institute of Nevada   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CYTOKINE; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

AGED; AMLODIPINE; ANALYSIS OF VARIANCE; CALCIUM CHANNEL BLOCKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030744382     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00145-9     Document Type: Article

References (48)

1. Yusuf S, Thom T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension. 13 Suppl:1989;I-74-I-79.
2. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s evolution of a major public health problem in cardiovascular medicine . J Am Coll Cardiol. 22:(Suppl A):1993;3A-5A.
3. Effects of enalapril on mortality in severe congestive heart failure results of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
4. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration Cooperative Study . N Engl J Med. 314:1986;1547-1552.
5. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
6. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
7. Packer M. Calcium channel blockers in chronic heart failure the risks of "physiologically rational" therapy . Circulation. 82:1990;2254-2257.
8. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 82:1990;1954-1961.
9. Packer M. The neurohormonal hypothesis a theory to explain the mechanism of disease progression in heart failure . J Am Coll Cardiol. 20:1992;248-254.
10. Hall C, Rouleau JL, Moye L, et al. N-terminal proatrial natriuretic factor an independent predictor of long-term prognosis after myocardial infarction . Circulation. 89:1994;1934-1942.
11. Han JJ, Windsor A, Drenning DH, et al. Release of endothelin in relation to tumor necrosis factor-alpha in porcine Pseudomonas aeruginosa-induced septic shock. Shock. 1:1994;343-346.
12. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
13. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation. 92:1995;1379-1382.
14. Ansari A. Syndromes of cardiac cachexia and the cachectic heart current perspective . Prog Cardiovasc Dis. 30:1987;45-60.
15. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy . Ann Intern Med. 113:1990;227-242.
16. Kitajima I, Kawahara K, Nakajima T, Soejima Y, Matsuyama T, Maruyama I. Nitric oxide-mediated apoptosis in murine mastocytoma. Biochem Biophys Res Commun. 204:1994;244-251.
17. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest. 95:1995;677-685.
18. Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat a synergistic effect with interleukin 1 . J Clin Invest. 83:1989;1614-1622.
19. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in cachectic patients with severe chronic heart failure. Br Heart J. 66:1991;356-358.
20. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J. 70:1993;141-143.
21. Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure relation to nitric oxide-dependent vasodilation in the forearm circulation . Circulation. 90:1994;12-16.
22. Biasucci LM, Ciliberto G, Liuzzo G, et al. Elevated serum concentrations of interleukin-6 in unstable angina [abstract]. Circulation. 92:(Suppl I):1995;I-664A.
23. Deng MC, Erren M, Kammerling L, et al. The relation of interleukin-6, tumor necrosis factor-alpha, IL-2, and IL-2 receptor levels to cellular rejection, allograft dysfunction, and clinical events early after cardiac transplantation. Transplantation. 60:1995;1118-1124.
24. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure Prospective Randomized Amlodipine Survival Evaluation study group . N Engl J Med. 335:1996;1107-1114.
25. Massie B, Bourassa M, DiBianco R, et al. Long-term oral administration of amrinone for congestive heart failure lack of efficacy in a multicenter controlled trial . Circulation. 71:1985;963-971.
26. Shah PK, Amin DK, Hulse S, Shellock F, Swan HJ. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043) poor long-term results despite early hemodynamic and clinical improvement . Circulation. 71:1985;326-331.
27. Petein M, Levine TB, Cohn JN. Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. J Am Coll Cardiol. 4:1984;364-371.
28. Maskin CS, Weber KT, Janicki JS. Long-term oral enoximone therapy in chronic cardiac failure. Am J Cardiol. 60:1987;63C-67C.
29. Weber KT, Janicki JS, Jain MC. Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure. Am Heart J. 114:1987;805-813.
30. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol. 22:1993;1897-1901.
31. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
32. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the Studies Of Left Ventricular Dysfunction (SOLVD) . J Am Coll Cardiol. 27:1996;1201-1206.
33. Ledur A, Fitting C, David B, Hamberger C, Cavaillon JM. Variable estimates of cytokine levels produced by commercial ELISA kits results using international cytokine standards . J Immunol Methods. 186:1995;171-179.
34. Kapadia S, Torre-Amione G, Mann DL. Pitfalls in measuring cytokines. Ann Intern Med. 121:1994;149-150.
35. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 92:1995;1487-1493.
36. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 175:1992;323-329.
37. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 151:1993;1548-1561.
38. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet. 347:1996;1151-1155.
39. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
40. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 63:1990;1149-1157.
41. Horsten U, Schmitz-Van de Leur H, Mullberg J, Heinrich PC, Rose-John S. The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor. FEBS Lett. 360:1995;43-46.
42. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 241:1988;825-828.
43. Ehlers M, Grotzinger J, deHon FD, et al. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol. 153:1994;1744-1753.
44. Mullberg J, Oberthur W, Lottspeich F, et al. The soluble human IL-6 receptor mutational characterization of the proteolytic cleavage site . J Immunol. 152:1994;4958-4968.
45. Mullberg J, Dittrich E, Graeve L, et al. Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett. 332:1993;174-178.
46. Mullberg J, Schooltink H, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 23:1993;473-480.
47. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 170:1989;1409-1414.
48. Rose-John S, Ehlers M, Grotzinger J, Mullberg J. The soluble interleukin-6 receptor. Ann N Y Acad Sci. 762:1995;207-220.